WEE1 inhibitor seeks accelerated approval in biomarker-selected PROC; single-arm DENALI data must clear FDA's bar

Zentalis is a clinical-stage company developing a targeted cancer drug for platinum-resistant ovarian cancer that is not yet approved.

Zentalis has built its entire value around azenosertib, a WEE1 kinase inhibitor that exploits replication stress in Cyclin E1-overexpressing platinum-resistant ovarian cancer, a molecularly defined patient subset with few effective options. The thesis resolves on whether DENALI Part 2 single-arm data produce an ORR sufficient to win FDA accelerated approval, with FDA's explicit acknowledgment of the pathway providing a real but conditional green light. The sharpest risk is approval-path dependent: single-arm accelerated approval remains subject to FDA's judgment on data strength, and $175M in cash with a late-2027 runway provides a narrow but real buffer past the 1H 2027 readout.